ALNY Stock Analysis: Alnylam Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 31.216m USD | 12M Return: -52.5% | US02043Q1076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 287M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotech company founded in 2002 that specializes in developing therapeutics based on RNA interference (RNAi), a technology that silences specific genes to treat or prevent disease. This RNAi platform approach is characteristic of a small group of biotech firms that have commercialized gene-silencing medicines, with Alnylam being the leader in the space.
The company markets six approved products, including ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, Leqvio (marketed with Novartis) for hypercholesterolemia, and Qfitlia for hemophilia A or B.
Alnylam maintains a deep development pipeline spanning Phase 1 through Phase 3 trials, targeting conditions across cardiometabolic, hepatic, neurological, and rare disease areas. Late-stage candidates include Nucresiran for ATTR amyloidosis, Zilebesiran for hypertension, Cemdisiran for myasthenia gravis and related disorders, and Elebsiran for hepatitis D.
The company pursues a partnership-heavy business model common in the biotechnology sector, with collaborations and licensing agreements with Regeneron, Roche, Sanofi, Novartis, PeptiDream, Dicerna, and Ionis Pharmaceuticals to extend the reach of its RNAi platform.
- Amvuttra drives TTR franchise revenue growth
- Zilebesiran Phase 3 hypertension data catalyzes pipeline value
- BridgeBio acoramidis threatens ATTR market share
| Net Income: 808.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 19.78 > 1.0 |
| NWC/Revenue: 64.69% < 20% (prev 95.16%; Δ -30.48% < -1%) |
| CFO/TA 0.11 > 3% & CFO 634.5m > Net Income 808.0m |
| Net Debt (-1.10b) to EBITDA (1.15b): -0.95 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago 6.61% < -2% |
| Gross Margin: 79.72% > 18% (prev 83.64%; Δ -3.92% > 0.5%) |
| Asset Turnover: 94.90% > 50% (prev 53.92%; Δ 40.98% > 0%) |
| Interest Coverage Ratio: 3.37 > 6 (EBIT TTM 1.10b / Interest Expense TTM 325.1m) |
| A: 0.56 (Total Current Assets 4.62b - Total Current Liabilities 1.51b) / Total Assets 5.56b |
| B: -1.14 (Retained Earnings -6.33b / Total Assets 5.56b) |
| C: 0.22 (EBIT TTM 1.10b / Avg Total Assets 5.06b) |
| D: 0.32 (Book Value of Equity 1.35b / Total Liabilities 4.20b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 0.82 (Receivables 912.7m/567.1m, Revenue 4.80b/2.46b) |
| GMI: 1.05 (GM 83.64% / 79.72%) |
| AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.95 (Revenue 4.80b / 2.46b) |
| TATA: 0.03 (NI 808.0m - CFO 634.5m) / TA 5.56b) |
| Beneish M = -2.61 (Cap -4..+1) = A |
As of October 22, 2026, the stock is trading at USD 225.10 with a total of 1,177,497 shares traded. Over the past week, the price has changed by +0.28%, over one month by -7.87%, over three months by -17.05% and over the past year by -52.51%.
Current recommended Stop Loss: 214.20 (which is 4.8% or 1.2 ATR below the current price).
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ALNY.
- StrongBuy: 17
- Buy: 6
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 368.7 | 63.8% |
P/E Trailing = 39.3406
P/E Forward = 19.685
P/S = 6.4977
P/B = 24.8672
P/EG = 0.3248
Revenue TTM = 4.80b USD
EBIT TTM = 1.10b USD
EBITDA TTM = 1.15b USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.9m USD (from shortTermDebt, last quarter)
Debt = 1.52b USD (from shortLongTermDebtTotal, last quarter) + Leases 256.4m
Net Debt = -1.10b USD (calculated: Debt 1.52b - CCE 2.62b)
Enterprise Value = 30.1b USD (31.2b + Debt 1.52b - CCE 2.62b)
Interest Coverage Ratio = 3.37 (Ebit TTM 1.10b / Interest Expense TTM 325.1m)
EV/FCF = 27.20x (Enterprise Value 30.1b / FCF TTM 1.11b)
FCF Yield = 3.68% (FCF TTM 1.11b / Enterprise Value 30.1b)
FCF Margin = 23.05% (FCF TTM 1.11b / Revenue TTM 4.80b)
Net Margin = 16.82% (Net Income TTM 808.0m / Revenue TTM 4.80b)
Gross Margin = 79.72% ((Revenue TTM 4.80b - Cost of Revenue TTM 974.3m) / Revenue TTM)
Gross Margin QoQ = 76.90% (prev 81.91%)
Tobins Q-Ratio = 5.42 (Enterprise Value 30.1b / Total Assets 5.56b)
Interest Expense / Debt = 21.33% (Interest Expense 325.1m / Debt 1.52b)
Taxrate = 7.49% (13.3m / 177.8m)
NOPAT = 1.01b (EBIT 1.10b * (1 - 7.49%))
Current Ratio = 2.85 (Total Current Assets 4.62b / Total Current Liabilities 1.62b)
Debt / Equity = 1.13 (Debt 1.52b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = -0.95 (Net Debt -1.10b / EBITDA 1.15b)
Debt / FCF = -0.99 (Net Debt -1.10b / FCF TTM 1.11b)
Total Stockholder Equity = 863.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.96% (Net Income 808.0m / Total Assets 5.56b)
RoE = 93.61% (Net Income TTM 808.0m / Total Stockholder Equity 863.1m)
RoCE = 58.48% (EBIT 1.10b / Capital Employed (Equity 863.1m + L.T.Debt 1.01b))
RoIC = 26.32% (NOPAT 1.01b / Invested Capital 3.85b)
WACC = 6.27% (E(31.2b)/V(32.7b) * Re(5.61%) + D(1.52b)/V(32.7b) * Rd(21.33%) * (1-Tc(0.07)))
Discount Rate = 5.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.15 | Cagr: 4.16%
[DCF] Terminal Value 77.97% ; FCFF base≈667.1m ; Y1≈764.8m ; Y5≈1.13b
[DCF] Fair Price = 134.8 (EV 16.9b - Net Debt -1.10b = Equity 18.0b / Shares 133.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: 94.81 | Revenue CAGR: 42.58% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.26 | Chg30d=-2.34% | Revisions=-40% | Analysts=13
EPS current Year (2026-12-31): EPS=8.92 | Chg30d=+0.79% | Revisions=-40% | GrowthEPS=+75.5% | GrowthRev=+47.5%
EPS next Year (2027-12-31): EPS=12.36 | Chg30d=-0.92% | Revisions=-40% | GrowthEPS=+38.6% | GrowthRev=+26.0%
[Analyst] Revisions Ratio: -67% (up=0, down=6)